Aragen secures $100 million investment from Quadria Capital

Aragen secures $100 million investment from Quadria Capital

By: IPP Bureau

Last updated : January 13, 2025 4:32 pm



Investment will fund expansion to meet rising demand for CRDMO services


Aragen, a globally renowned Contract Research, Development and Manufacturing Organization (CRDMO), has secured a US$ 100 million investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of US$ 1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors.

This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe.

With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen.

“We are delighted to welcome Quadria to Aragen. This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” said Manni Kantipudi, CEO, Aragen Life Science. “Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently.”

Dr. Amit Varma, Managing Partner and co-Founder of Quadria Capital, said, "The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganization. Aragen's impressive track record, customer-centric approach, and commitment to innovation make it an ideal partner for global pharmaceutical companies. We look forward to partnering with them and supporting their next phase of growth."

This investment marks another milestone in Quadria’s continued focus on high-growth opportunities in the healthcare sector. Quadria has a strong track-record of successful investments in leading outsourced pharmaceutical services companies, including Akums Drugs (India’s largest domestic focused contract manufacturer), Encube Ethicals (India-based topicals focused CDMO) and Straits Orthopedics (Malaysia-based CDMO for orthopedic medical devices).

Aragen Contract Research Development and Manufacturing Organization CRDMO Quadria Capital healthcare Private Equity fund Manni Kantipudi Aragen Life Science Dr. Amit Varma Akums Drugs Encube Ethicals Straits Orthopedics

First Published : January 13, 2025 12:00 am